Pipeline
Core Global Development Pipeline of ONO
Oncology
As of 25 Apr, 2023
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| ONO-4059 | BTK inhibitor | Primary central nervous system lymphoma | JP・KR・TW | In-house | |||||
| US | |||||||||
| Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma | JP | ||||||||
| ONO-7475 | Axl/Mer inhibitor | Solid tumor ★ | JP | In-house | |||||
| EGFR mutation-positive non-small cell lung cancer | JP | ||||||||
| ONO-4685 | PD-1 x CD3 bispecific antibody | T-cell lymphoma | US | In-house | |||||
| ONO-4578 | PG receptor (EP4) antagonist | Solid tumor・Gastric cancer ★ | JP | In-house | |||||
| Colorectal cancer ★ | JP | ||||||||
| Pancreatic cancer ★ | JP | ||||||||
| Non-small cell lung cancer ★ | JP | ||||||||
| Hormone receptor-positive, HER2-negative breast cancer | JP | ||||||||
| ONO-7914 | STING agonist | Solid tumor ★ | JP | In-house | |||||
| ONO-7018 | MALT1 Inhibitor | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia | US | Chordia | |||||
★Combination with Nivolumab
Other than oncology
As of 25 Apr, 2023
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| ONO-4059 | BTK inhibitor | Pemphigus | JP | In-house | |||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Diabetic polyneuropathy | JP | In-house | |||||
| ONO-4685 | PD-1 x CD3 bispecific antibody | Autoimmune disease | JP・EU | In-house | |||||
| ONO-2808 | S1P5 receptor agonist | Neurodegenerative disease | JP・EU | In-house | |||||
| ONO-7684 | FXla inhibitor | Thrombosis | JP・EU | In-house | |||||
| ONO-2020 | Epigenetic Regulation | Neurodegenerative disease | US | In-house | |||||
| ONO-1110 | Endocannabinoid regulation | Pain | JP | In-house | |||||
